ERBB2 and breast cancer: While ATG12 isnot currently a druggable target, emerging autophagy inhibitors (e.g., Lys05,Spautin-1) that target other components of the autophagic vesicle assembly [102-104] may prove to be an effectivemeans to circumvent primary resistance to and potentiate the efficacy of HER2-targeting strategiescurrently in use in HER2-positive breast cancer patients.